強直性脊椎炎治療薬市場- 世界の産業規模、シェア、動向、機会、予測、医薬品別、最終用途別、地域別、競合別、2020-2030年

強直性脊椎炎（AS）治療薬の世界市場規模は2024年に51億米ドルとなり、予測期間中は堅調な成長が見込まれ、2030年までの年間平均成長率（CAGR）は7.45％を記録する見込みです。

強直性脊椎炎は慢性の炎症性自己免疫疾患であり、主に脊椎を侵し、持続的な疼痛、こわばり、運動能力の低下をもたらします。脊椎関節炎の一群に分類されるASは、末梢の関節や様々な臓器を侵すこともあります。AS治療薬市場は、臨床研究の進歩、新規治療法の導入、疾患に対する世界の認知度の向上などに後押しされ、近年著しい発展を遂げています。

ASは、背骨の付け根にある仙骨と骨盤をつなぐ仙腸関節の炎症が特徴です。この炎症が長期化すると脊椎の椎骨が癒合し、脊椎の柔軟性が著しく制限され、姿勢が変化します。一般的に成人期早期に発症し、一般的な症状としては腰痛や朝のこわばりがあります。患者の生活の質を高めるためには、適時の診断と効果的な疾患管理が不可欠です。

強直性脊椎炎は世界の健康問題であり、世界中で数百万人が罹患しています。有病率は地域や人口によって異なり、特にHLA-B27遺伝子を中心とする遺伝的要因が疾患開発に大きな役割を果たしています。AS治療薬市場は、診断の早期化、治療へのアクセスの向上、先進的な治療薬の登場により、近年大幅に拡大しています。

主な市場促進要因

強直性脊椎炎の有病率の上昇

ASの早期診断が可能になったことで、より早期の治療介入が可能になり、長期的な治療継続性が向上し、治療製品に対する持続的な需要が高まっています。

主な市場課題

認知度の低下と診断の遅れ

主な市場動向

診断と治療における技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 強直性脊椎炎治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤別（コセンティクス、ヒュミラ、シンポニ、レミケード、エンブレル、シムジア）
  • 用途別（病院、診療所、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の強直性脊椎炎治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の強直性脊椎炎治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の強直性脊椎炎治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の強直性脊椎炎治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの強直性脊椎炎治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の強直性脊椎炎治療薬市場：SWOT分析

第14章 競合情勢

• AbbVie, Inc.
• Amgen, Inc.
• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• UCB, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Ankylosing Spondylitis (AS) therapeutics market was valued at USD 5.10 billion in 2024 and is expected to witness robust growth during the forecast period, registering a compound annual growth rate (CAGR) of 7.45% through 2030.

Ankylosing spondylitis is a chronic, inflammatory autoimmune disorder that predominantly affects the spine, leading to persistent pain, stiffness, and reduced mobility. Classified within the group of spondyloarthritis disorders, AS can also involve peripheral joints and various organs. The market for AS therapeutics has experienced notable progress in recent years, fueled by advancements in clinical research, the introduction of novel treatment modalities, and increased global awareness of the disease.

AS is marked by inflammation of the sacroiliac joints, connecting the sacrum at the base of the spine to the pelvis. Over time, this inflammation can result in the fusion of spinal vertebrae, severely limiting spinal flexibility and altering posture. Typically manifesting in early adulthood, common symptoms include lower back pain and morning stiffness. Timely diagnosis and effective disease management are essential to enhancing patients' quality of life.

Ankylosing spondylitis is a global health concern, affecting millions of individuals worldwide. Prevalence rates vary by region and population, with genetic factors-particularly the HLA-B27 gene-playing a major role in disease development. The AS therapeutics market has expanded considerably in recent years due to earlier diagnoses, increased treatment accessibility, and the availability of advanced therapeutics.

Key Market Drivers

Rising Prevalence of Ankylosing Spondylitis

The increasing global incidence of ankylosing spondylitis is a primary driver of market growth. Although AS affects a relatively small proportion of the population-ranging from 0.1% to 1.4%-its impact is significant, particularly among males and individuals in their most productive working years, often beginning in their mid-20s.

This growing patient base is intensifying the demand for effective, long-term therapeutic solutions, creating ample opportunities for pharmaceutical manufacturers and healthcare providers. Traditionally underdiagnosed due to its insidious onset and nonspecific symptoms, AS is now being identified earlier thanks to heightened awareness and advancements in diagnostic imaging technologies.

The ability to diagnose AS in its early stages enables earlier intervention, which enhances long-term treatment adherence and drives sustained demand for therapeutic products.

Key Market Challenges

Limited Awareness and Delayed Diagnosis

One of the core challenges faced by the AS therapeutics market is the limited awareness among both healthcare professionals and the general public. Misdiagnosis or late diagnosis remains a common issue, often resulting in delayed treatment and worsened patient outcomes. Addressing this gap through education and awareness campaigns is vital to improving early detection and disease management.

Key Market Trends

Technological Advancements in Diagnosis and Treatment

Emerging technologies have significantly improved the diagnostic accuracy and management of ankylosing spondylitis. Imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) are now routinely employed to detect early signs of inflammation and structural damage in the spine and sacroiliac joints. These high-resolution tools facilitate early diagnosis, which is crucial for initiating timely treatment.

Additionally, the integration of artificial intelligence (AI) and machine learning in image analysis has enhanced diagnostic precision. AI-driven tools are capable of identifying subtle pathological changes that might be overlooked by human evaluators, further supporting early and accurate diagnosis.

On the treatment front, advancements in biotechnology have led to the development of biological therapies-targeted drugs that address the specific immune mechanisms driving AS-related inflammation. TNF inhibitors have significantly improved patient outcomes by alleviating pain, stiffness, and inflammation. Furthermore, the emergence of biosimilars-cost-effective alternatives to biologic drugs-has broadened patient access to these life-changing treatments, especially in cost-sensitive markets.

Key Market Players

• AbbVie, Inc.
• Amgen, Inc.
• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• UCB, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc

Report Scope:

In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ankylosing Spondylitis Therapeutics Market, By Drug:

• Cosentyx
• Humira
• Simponi
• Remicade
• Enbrel
• Cimzia

Ankylosing Spondylitis Therapeutics Market, By End Use:

• Hospitals
• Clinics
• Others

Ankylosing Spondylitis Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.

Available Customizations:

Global Ankylosing Spondylitis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Ankylosing Spondylitis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia)
  • 5.2.2. By End Use (Hospitals, Clinics, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Ankylosing Spondylitis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Ankylosing Spondylitis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By End Use
  • 6.3.2. Canada Ankylosing Spondylitis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By End Use
  • 6.3.3. Mexico Ankylosing Spondylitis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By End Use

7. Europe Ankylosing Spondylitis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By End Use
  • 7.3.2. United Kingdom Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By End Use
  • 7.3.3. Italy Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By End Use
  • 7.3.4. France Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By End Use

8. Asia-Pacific Ankylosing Spondylitis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By End Use
  • 8.3.3. Japan Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By End Use
  • 8.3.4. South Korea Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By End Use

9. South America Ankylosing Spondylitis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Ankylosing Spondylitis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Ankylosing Spondylitis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Ankylosing Spondylitis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Ankylosing Spondylitis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Ankylosing Spondylitis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Ankylosing Spondylitis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Ankylosing Spondylitis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Ankylosing Spondylitis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AbbVie, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Amgen, Inc.
• 14.3. Pfizer, Inc.
• 14.4. Novartis AG
• 14.5. Eli Lilly and Company
• 14.6. UCB, Inc.
• 14.7. Johnson & Johnson Services, Inc.
• 14.8. Merck & Co., Inc

15. Strategic Recommendations

16. About Us & Disclaimer